Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 29

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 29
---
, as of [ ], 2025. We may issue additional shares of preferred stock, in series, with such designations, powers, preferences and other rights and qualifications, limitations or restrictions as our board of directors may authorize, without further action by our stockholders, including:

| • |     | the distinctive designation of each series and the number of shares that will constitute the series; |

| • |     | the voting rights, if any, of shares of the series and the terms and conditions of the voting rights; |

| • |     | the dividend rate on the shares of the series, the dates on which dividends are payable, any restriction,                                                   
 limitation or condition upon the payment of dividends, whether dividends will be cumulative, and the dates from and after which dividends shall accumulate; |

| • |     | the prices at which, and the terms and conditions on which, the shares of the series may be redeemed, if the 
 shares are redeemable;                                                                                       |

| • |     | the terms and conditions of a sinking or purchase fund for the purchase or redemption of shares of the series, if 
 such a fund is provided;                                                                                          |

| • |     | any preferential amount payable upon shares of the series in the event of the liquidation, dissolution or winding 
 up of, or upon the distribution of any of our assets; and                                                         |

18

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83

| • |     | the prices or rates of conversion or exchange at which, and the terms and conditions on which, the shares of the 
 series may be converted or exchanged into other securities, if the shares are convertible or exchangeable.       |

The particular terms of any additional series of preferred stock, and the transfer agent and registrar for that series, will be described in a prospectus supplement. Any material United States federal income tax consequences and other special considerations with respect to any preferred stock offered under this prospectus will also be described in the applicable prospectus supplement. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock. The issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company, which could depress the market price of our common stock. Series B Preferred Stock Conversion.Each share of Series B Preferred